中国组织工程研究

中国组织工程研究 ›› 2012, Vol. 16 ›› Issue (2): 377-380.doi: 10.3969/j.issn.1673-8225.2012.02.042

• 组织构建临床实践 clinical practice in tissue construction • 上一篇    

尿道黏膜下注射维拉帕米预防前尿道狭窄尿道内切开后的复发：24个月随访证实钙离子阻滞的作用**★

许  宁，薛学义，周辉良，魏  勇，高  锐，毛厚平   

  1. 福建医科大学附属第一医院泌尿外科，福建省福州市  350005
  • 收稿日期:2011-06-19 修回日期:2011-09-26 出版日期:2012-01-08 发布日期:2012-01-08
  • 作者简介:许宁★，男，1982年生，福建省福清市人，汉族，硕士，主要从事前列腺、尿道外科疾病的研究。
  • 基金资助:

    基金资助：福建省卫生厅青年科研基金(2009-2-16)；福建医科大学教授基金(JS10017)。

Submucosal injection of verapamil prevents anterior urethral stricture recurrence following internal urethrotomy**★

Xu Ning, Xue Xue-yi, Zhou Hui-liang, Wei Yong, Gao Rui, Mao Hou-ping   

  1. Department of Urology, First Affiliated Hospital of Fujian Medical University, Fuzhou  350005, Fujian Province, China
  • Received:2011-06-19 Revised:2011-09-26 Online:2012-01-08 Published:2012-01-08
  • About author:Xu Ning★, Master, Department of Urology, First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, Fujian Province, China drxun@163.com
  • Supported by:
    the Youth Foundation of Fujian Province Health Department, No. 2009-2-16*; the Professor Foundation of Fujian Medical University, No. JS10017*
     

PDF

497

摘要：

背景：尿道内切开术治疗前尿道狭窄简单易行，但存在远期狭窄复发率高的缺点。
目的：观察尿道黏膜下注射维拉帕米在预防前尿道狭窄尿道内切开术后狭窄复发中的作用。
方法：纳入2006-12/2008-04在福建医科大学附属第一医院泌尿外科治疗的前尿道狭窄患者60例，随机分为2组：一组行尿道内切开，另一组在行尿道内切开的同时加用维拉帕米行尿道黏膜下注射。所有患者至少随访24个月。
结果与结论：患者随访24~39个月，平均28.5个月。尿道内切开组中有8例狭窄复发，而尿道内切开同时加用维拉帕米黏膜下注射组中仅有2例尿道狭窄复发。两组间比较差异有显著性意义(P < 0.05)。说明尿道内切开同时加用维拉帕米行尿道黏膜下注射可以预防内切开后尿道狭窄的复发，但更确切的结论需要更长时间的随访和更多病例来证实。

关键词: 维拉帕米, 尿道内切开, 前尿道狭窄, 复发, 随访

Abstract:

BACKGROUND: It is easy and feasible to treat anterior urethral stricture using internal urethrotomy, however, its drawback is high recurrence in the long-term follow-up.
OBJECTIVE: To evaluate the effect of submucosal injected verapamil on prevention of anterior urethral stricture recurrence after internal urethrotomy.
METHODS: Totally 60 consecutive males with anterior urethral stricture underwent internal urethrotomy with or without urethral submucosal injection of verapamil, in the Department of Urology, First Affiliated Hospital of Fujian Medical University, from December 2006 to April 2008, were selected. All cases were followed up at least 24 months.
RESULTS AND CONCLUSION: All cases were followed up for 24-39 months, with an average of 28.5 months. Urethral stricture recurred in two cases in the verapamil-treated group but 8 cases in the untreated group. This difference in stricture recurrence between the two groups was statistically significant (P < 0.05). The results demonstrated that submucosal injection of verapamil at the stricture site significantly reduces the stricture recurrence rate after internal urethrotomy. Further studies involving larger number of cases and longer follow-up are warranted to confirm the efficacy and safety of this therapy.

中图分类号: